Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

A Study of RO5313534 as Add-on to Donepezil Treatment in Patients With Mild to Moderate Alzheimer's Disease

Phase 2

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: RO5313534
Drug: Placebo

First Posted Date: 2009-04-20

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 389

Registration Number: NCT00884507

A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Phase 3

Completed

Conditions: Non-Squamous Non-Small Cell Lung Cancer

Interventions: Drug: Platinum chemotherapy (cisplatin or carboplatin)
Drug: Placebo
Drug: erlotinib [Tarceva]
Drug: gemcitabine

First Posted Date: 2009-04-20

Last Posted Date: 2015-12-14

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 451

Registration Number: NCT00883779

An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: tocilizumab [RoActemra/Actemra]

First Posted Date: 2009-04-20

Last Posted Date: 2014-08-06

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 934

Registration Number: NCT00883753

A Study of Once Monthly Subcutaneous Mircera in Dialysis Patients With Chronic Renal Anemia

Phase 3

Completed

Conditions: Anemia

Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera]

First Posted Date: 2009-04-16

Last Posted Date: 2016-10-07

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 202

Registration Number: NCT00882713

A Study to Evaluate the Biological Activity of R1507 in Women With Operable Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: RG1507

First Posted Date: 2009-04-16

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 8

Registration Number: NCT00882674

Effect of TRO19622 in the Treatment of Patients With Chemotherapy Induced Peripheral Neuropathy

Phase 2

Completed

Conditions: Chemotherapy-Induced Peripheral Neuropathy

Interventions: Drug: Olesoxime (TRO19622)
Drug: Placebo Control

First Posted Date: 2009-04-06

Last Posted Date: 2016-11-22

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 17

Registration Number: NCT00876538

Locations: 🇫🇷
Centre Antoine Lacassagne, Nice, France
🇫🇷
C.R.L.C Val d'Aurelle Service d'Oncologie Médicale, Montpellier, France
🇫🇷
Centre Hospitalier de Versailles Hôpital André Mignot Service d'Hématologie-Oncologie, Le Chesnay, France

and more 5 locations

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab

Phase 1

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Trastuzumab emtansine [Kadcyla] 3.0 mg/kg
Drug: Trastuzumab emtansine [Kadcyla] 3.6 mg/kg
Drug: Pertuzumab 420 mg

First Posted Date: 2009-04-06

Last Posted Date: 2013-12-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 67

Registration Number: NCT00875979

A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4

Phase 2

Completed

Conditions: Hepatitis C, Chronic

Interventions: Drug: Copegus
Drug: Pegasys
Drug: RO5024048

First Posted Date: 2009-03-26

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 413

Registration Number: NCT00869661

Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From ALS

Phase 3

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Olesoxime
Drug: Placebo Comparator
Drug: Riluzole

First Posted Date: 2009-03-24

Last Posted Date: 2020-02-25

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 512

Registration Number: NCT00868166

Locations: 🇧🇪
University Hospital Gasthuisberg - Dept Neurology - Herestraat 49, Leuven, Belgium
🇫🇷
Hôpital La Timone - Service Neurologie et Maladies Neuromusculaires, Marseille, France
🇫🇷
Clinique du Motoneurone - Sce d'Explorations Neurologiques - Hôpital Gui de Chauliac, Montpellier, France

and more 12 locations

A Study of Bevacizumab (Avastin) in Participants With Newly Diagnosed Locally Advanced Rectal Cancer

Phase 2

Completed

Conditions: Rectal Cancer

Interventions: Drug: Bevacizumab
Drug: Oxaliplatin
Drug: Folinic Acid
Drug: 5-fluorouracil
Radiation: Preoperative Radiotherapy
Procedure: Surgery

First Posted Date: 2009-03-19

Last Posted Date: 2017-08-04

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 91

Registration Number: NCT00865189

Locations: 🇫🇷
ICO Paul Papin; Oncologie Medicale., Angers, France
🇫🇷
HOPITAL JEAN MINJOZ; Oncologie, Besancon, France
🇫🇷
Hopital Saint Andre; Département de Radiothérapie Et D'Oncologie Médicale, Bordeaux, France

and more 17 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy